Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) were down 0.7% during mid-day trading on Friday after Barclays lowered their price target on the stock from $1,025.00 to $975.00. Barclays ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) fell 6% during trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $769.00 ...

Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...

Nearly one-third of those patients were paying $35 or far more per month in 2019, according to the latest available data from ...

The global injection pen market is expanding at a fast rate with the growing prevalence of chronic diseases, and increasing demand for convenient self-administration options. This trend is a move ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Now, scientists have made a major breakthrough in developing what has been long called the “holy grail” diabetes treatments — a “smart” insulin that responds in real time to fluctuations in one’s ...

A new treatment combining ReCET and semaglutide eliminated insulin use in 86% of type 2 diabetes patients, improving natural insulin sensitivity. A new treatment combining ReCET and semaglutide could ...

“Notably, glucose values vary over a narrow range (from approximately 2 to 20-30 mM [36 mg/dL to 360-540 mg/dL] in people with diabetes), so a rather steep change in insulin bioactivity must be ...